Group 1 - The core point of the article is that KangNeng Health (300272) has reported a total of 31,350 shareholders as of November 20, 2025 [1]

Group 1 - Beijing Junzheng adjusted management expenses by 11.44 million yuan, increasing net profit by the same amount [1] - Ningbo Energy's subsidiary plans to publicly transfer 15% equity of Lingfeng Energy at a base price of 16.06 million yuan [1] - Dongjiang Environmental's subsidiary was fined 2.02 million yuan for tax evasion [1][2] Group 2 - AVIC's subsidiary Harbin Aircraft Industry Group plans to absorb and merge with Harbin Hafei Aviation, increasing registered capital to 3.038 billion yuan [3] - Dongfang Ocean's shareholder plans to reduce holdings by up to 3% of total shares [4] - Xinghui Entertainment's controlling shareholder plans to reduce holdings by up to 2.9% of total shares [6] Group 3 - Kaineng Health plans to acquire 100% equity of four subsidiaries for 204 million yuan [8] - Suoao Sensor's controlling shareholder changed to Zhongchuang Innovation [9] - Shanghai Port Bay reported that its commercial aerospace and perovskite solar business accounts for less than 1% of revenue [10] Group 4 - Zhonghuan Environmental's specific shareholder plans to reduce holdings by up to 2.37% of total shares [11] - Xinlaifu's asset management plan intends to reduce 874,300 shares [12] - Guangdian Measurement plans to invest 800 million yuan to build a testing base [13] Group 5 - Modern Investment plans to invest 1.04 billion yuan to establish a smart logistics company [14] - Gaole Co.'s major shareholder is planning a control change, leading to stock suspension [16] - Weiling Co.'s major shareholder is planning a control change, leading to stock suspension [18] Group 6 - Igor plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [20] - Huanrui Century's shareholder sold 7.26 million shares due to judicial enforcement [21] - Jinhua Co.'s controlling shareholder plans to acquire 5.77% of company shares at 9.15 yuan per share [22] Group 7 - Wireless Media's four shareholders plan to reduce holdings by up to 4.7% of total shares [24] - CATL's shareholder completed the transfer of 10% of shares for approximately 17.16 billion yuan [26] - *ST Lian Stone entered the restructuring phase, with potential downward adjustment of stock price [28]

Core Insights - The company, Kaineng Health, is a global provider of comprehensive solutions and products for water treatment in residential settings [1] - Kaineng Health pioneered the concept of "whole-house water purification" in China in 2001 and has focused on the research, manufacturing, sales, and service of various water treatment products and core components [1] Financial Performance - For the period from January to September 2025, Kaineng Health achieved a revenue of 1.356 billion yuan, representing a year-on-year growth of 8.10% [1] - The company reported a net profit attributable to the parent company of 95 million yuan, which is a year-on-year increase of 13.29% [1]

Core Viewpoint - The company, Kaineng Health, is expanding its investment in the cell industry by acquiring 100% equity stakes in several subsidiaries of Yuanneng Group for a total transaction price of 204 million yuan, aiming to enhance its growth trajectory in the health sector [1][4]. Group 1: Transaction Details - Kaineng Health's wholly-owned subsidiary, Hainan Kaineng Cell Industry, signed an equity acquisition agreement with Yuanneng Group and its subsidiary Yuanneng Lishui, purchasing stakes in Shanghai Yuantian Biotechnology, Lishui Dongxin Pharmaceutical, Shanghai Kelemao Biotechnology, and Jiyuan Meiyu Biotechnology for 204 million yuan [1][4]. - The transaction involves related parties, as Kaineng Health holds a 43.7% stake in Yuanneng Group, with its chairman and actual controller being the same individual as Yuanneng Group's actual controller [3]. Group 2: Background of Yuanneng Group - Yuanneng Group was established in July 2014 with an initial investment of 100 million yuan, which has increased to a registered capital of 546 million yuan as of now [2][3]. - The group operates in the Zhangjiang Biomedical Industry Base, covering 80 acres with a total construction area of approximately 80,000 square meters, focusing on third-party cell storage and downstream applications such as stem cell drug development and immune cell drug research [2][3]. Group 3: Strategic Intent - Kaineng Health aims to strengthen its investment layout in the cell industry, leveraging its existing business in health and environmental purification to create a second growth curve [4]. - The company plans to provide resource support to the acquired entities, enhancing their development and increasing investment in the health sector to diversify its product offerings and improve competitive strength [4].

Core Viewpoint - Kaineng Health announced a cash acquisition of equity stakes in subsidiaries of Yuaneng Group, indicating strategic growth plans in the environmental equipment manufacturing and service sector [1] Company Summary - Kaineng Health's revenue composition for the year 2024 is entirely from the environmental equipment manufacturing and service industry, accounting for 100.0% [1] - As of the report, Kaineng Health has a market capitalization of 4.4 billion yuan [1] Industry Summary - The announcement reflects ongoing consolidation and investment activities within the environmental equipment sector, highlighting potential growth opportunities [1]

格隆汇11月24日丨开能健康(300272.SZ)公布，公司的全资子公司海南开能细胞与原能集团及原能丽水 签订《关于原能细胞科技集团股份有限公司子公司之股权收购协议》，海南开能细胞以现金方式收购原 能丽水持有的原天生物、丽水东昕100%股权及原能集团持有的克勒猫、基元美业100%股权。本次交易 不会对公司本年度财务状况及经营成果造成重大影响。 本次交易以符合《证券法》规定的资产评估机构出具的模拟合并主体资产评估报告中的评估结果作为定 价依据，最终确定本次交易标的股权的转让价款为20,381.66万元。本次收购后，公司将持有原天生物、 基元美业、丽水东昕、克勒猫100%股权，公司合并报表范围将新增以上公司及其控股子公司（上海东 昕、莱森原、欧珊尔）。 由于本次交易目标公司均属于原能集团同一控制的主体，在原能集团的合并范围内，因此，本次收购完 成后，上述主体均将被开能健康的细胞业务子公司海南开能细胞控制，收购前后保持同一控制的相互关 系。其次，原天生物、丽水东昕和基元美业同属细胞产业链上下游关系，相互之间存在业务协同，如： 原天生物为基元美业提供细胞因子化妆品的研发支持和原料供应；原天生物为莱森原提供宠物保健抗衰 ...

Core Viewpoint - The company announced a cash acquisition of 100% equity stakes in several subsidiaries of Yuan Neng Group, which will enhance its control over the cell industry value chain and create business synergies [1][2] Group 1: Acquisition Details - The acquisition involves Hainan Kaineng Cell acquiring 100% equity of Yuan Tian Biological, Lishui Dongxin, Kele Cat, and Jiyuan Meiyu from Yuan Neng Group [1] - The total transaction price is set at 203.82 million yuan [2] - The acquired companies are all under the same control of Yuan Neng Group, ensuring continuity in management and operational relationships post-acquisition [1] Group 2: Business Synergies - Yuan Tian Biological provides research and raw material support for Jiyuan Meiyu's cell factor cosmetics [1] - Yuan Tian Biological also offers technical support for pet health and anti-aging business to Laisenyuan [1] - Lishui Dongxin's subsidiary, Shanghai Dongxin, operates the Yuan Neng Pharmaceutical Park, indicating a tight business and ecological relationship among the acquired entities [1]

开能健康11月24日公告，公司全资子公司海南开能细胞拟以现金方式收购原能集团部分新培育项目子公 司的全部出资，包括上海原天生物科技有限公司、丽水东昕药业有限公司、基元美业生物科技（上海） 有限公司、上海克勒猫生物科技有限公司各公司100%股权。交易价格为2.04亿元。本次交易构成关联 交易，不构成重大资产重组。 ...

长江证券承销保荐有限公司 关于开能健康全资子公司收购原能集团部分子公司股权 暨关联交易的核查意见 作为开能健康科技集团股份有限公司（以下简称"开能健康"或"公司")持续 督导的保荐人，根据《证券发行上市保荐业务管理办法》《深圳证券交易所上市公司 自律监管指引第 2 号—创业板上市公司规范运作》及《深圳证券交易所创业板股票 上市规则》等文件的规定，长江证券承销保荐有限公司（以下简称"长江保荐"或"保 荐人"）对开能健康科技集团股份有限公司全资子公司现金收购原能细胞科技集团 股份有限公司部分子公司暨关联交易事项进行了核查，具体核查情况如下： 1 开能健康、公 司、本公司、上 市公司 指 开能健康科技集团股份有限公司 海南开能细胞 指 开能健康细胞产业（海南）有限公司 丽水东昕 指 丽水东昕药业有限公司 原天生物 指 上海原天生物科技有限公司 基元美业 指 基元美业生物科技（上海）有限公司 克勒猫 指 上海克勒猫生物科技有限公司 目标公司、交易 标的、标的公司 指 克勒猫、丽水东昕、原天生物、基元美业 欧珊尔 指 上海欧珊尔生物科技有限公司 上海东昕 指 上海东昕生物技术有限公司 莱森原 指 上海莱森原生命科学有限 ...

证券代码：300272 证券简称：开能健康 公告编号：2025-095 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别内容提示： 1、本次交易构成关联交易，不构成《上市公司重大资产重组管理办法》规 定的重大资产重组，根据《深圳证券交易所创业板股票上市规则》《深圳证券交 易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》以及《公司章 程》等相关规定，本次交易经公司董事会审议通过后，尚需提交股东会审议。 2、本次交易拟取得上海原天生物科技有限公司、丽水东昕药业有限公司、 基元美业生物科技（上海）有限公司、上海克勒猫生物科技有限公司各公司 100% 股权，目标公司所处细胞行业具有一定的前瞻性，技术产品虽然已经成熟，但上 述公司的未来经营成果和盈利能力受在研项目研发进展、产品商业化进展、行业 监管政策、市场竞争格局和宏观经济波动等多种因素的影响，存在一定的不确定 性。 本次交易有利于公司大健康产业布局和未来经济效益提升，对公司 2025 年 度报告期的营业收入、净利润预计不会构成重大不利影响。 3、本次交易目标公司的定价以评估结论为参考依据，相对账面 ...